Aileron Therapeutics (ALRN) Stock Forecast, Price & News

Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

Is Aileron Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aileron Therapeutics stock.
View analyst ratings for Aileron Therapeutics or view top-rated stocks.

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 153,600 shares, a decline of 17.0% from the April 15th total of 185,100 shares. Based on an average trading volume of 360,700 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.2% of the company's shares are short sold.
View Aileron Therapeutics' Short Interest.

When is Aileron Therapeutics' next earnings date?

Aileron Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Aileron Therapeutics.

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) issued its quarterly earnings results on Thursday, May, 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01.
View Aileron Therapeutics' earnings history.

What price target have analysts set for ALRN?

3 analysts have issued 12-month price objectives for Aileron Therapeutics' shares. Their forecasts range from $2.00 to $5.00. On average, they expect Aileron Therapeutics' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 695.5% from the stock's current price.
View analysts' price targets for Aileron Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the following people:

• Dr. Manuel C. Aivado, Pres, CEO & Director (Age 52, Pay $1.06M)
• Mr. Richard J. Wanstall M.B.A., SVP, CFO & Treasurer (Age 53, Pay $551.69k)
• Dr. Vojislav Vukovic M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 55, Pay $676.44k)
• Dr. D. Allen Annis Ph.D., Sr. VP of Research (Age 49)

Who are some of Aileron Therapeutics' key competitors?

Some companies that are related to Aileron Therapeutics include Humanigen (HGEN), Harrow Health (HROW), Clene (CLNN), Savara (SVRA), Impel NeuroPharma (IMPL), Matinas BioPharma (MTNB), PDS Biotechnology (PDSB), IO Biotech (IOBT), Ovid Therapeutics (OVID), Xeris Biopharma (XERS), Actinium Pharmaceuticals (ATNM), Actinium Pharmaceuticals (ATNM), Assertio (ASRT), TFF Pharmaceuticals (TFFP) and ContraFect (CFRX).
View all of ALRN's competitors.

What other stocks do shareholders of Aileron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX) and Nabriva Therapeutics (NBRV).

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Who are Aileron Therapeutics' major shareholders?

Aileron Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.41%), Blair William & Co. IL (1.11%), Bailard Inc. (0.14%) and Renaissance Technologies LLC (0.06%). Company insiders that own Aileron Therapeutics stock include Muneer A Satter, Reinhard J Ambros and Rickenbach Josef H Von.
View institutional ownership trends for Aileron Therapeutics.

Which major investors are selling Aileron Therapeutics stock?

ALRN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., and Blair William & Co. IL.
View insider buying and selling activity for Aileron Therapeutics or view top insider-selling stocks.

Which major investors are buying Aileron Therapeutics stock?

ALRN stock was purchased by a variety of institutional investors in the last quarter, including Bailard Inc.. Company insiders that have bought Aileron Therapeutics stock in the last two years include Muneer A Satter, Reinhard J Ambros, and Rickenbach Josef H Von.
View insider buying and selling activity for Aileron Therapeutics or or view top insider-buying stocks.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $0.44.

How much money does Aileron Therapeutics make?

Aileron Therapeutics has a market capitalization of $39.96 million. The company earns $-26.16 million in net income (profit) each year or ($0.300010) on an earnings per share basis.

How many employees does Aileron Therapeutics have?

Aileron Therapeutics employs 9 workers across the globe.

What is Aileron Therapeutics' official website?

The official website for Aileron Therapeutics is www.aileronrx.com.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at (617) 995-0900 or via email at [email protected].